Patents Assigned to Inserm
-
Publication number: 20220195035Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: March 7, 2022Publication date: June 23, 2022Applicants: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Publication number: 20220193252Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.Type: ApplicationFiled: December 22, 2021Publication date: June 23, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTESInventors: Mathieu MEVEL, David DENIAUD, Eduard AYUSO
-
Patent number: 11365251Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).Type: GrantFiled: October 27, 2020Date of Patent: June 21, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Patent number: 11365257Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.Type: GrantFiled: October 20, 2017Date of Patent: June 21, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICSInventors: Elise Chiffoleau, Géraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
-
Patent number: 11364219Abstract: The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.Type: GrantFiled: May 19, 2017Date of Patent: June 21, 2022Assignees: INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LILLE, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CRNS—Inventor: Mathias Chamaillard
-
Patent number: 11365392Abstract: The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4+ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR??+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR??+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.Type: GrantFiled: August 4, 2017Date of Patent: June 21, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), MEDECINE ET INNOVATION, UNIVERSITÉ PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Daniel Zagury, Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan
-
Patent number: 11364271Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.Type: GrantFiled: April 19, 2019Date of Patent: June 21, 2022Assignees: INSERM, Etablissement Français Du Sang (EFS), Université De Bretagne Occidentale, Centre Hospitalier Regional et Universitaire de BrestInventors: Rozenn Le Berre, Marie-Sarah Fangous, Gwenaelle Le Blay, Geneviève Hery-Arnaud, Rosyne Lagrafeuille
-
Patent number: 11357778Abstract: The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.Type: GrantFiled: October 24, 2019Date of Patent: June 14, 2022Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, IMAGINEInventors: Laurence Legeai-Mallet, Arnold Munnich, Patricia Busca, Florent Barbault
-
Patent number: 11357816Abstract: The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.Type: GrantFiled: June 17, 2019Date of Patent: June 14, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), SORBONNE UNIVERSITE, ECOLE NORMALE SUPERIEURE, COLLEGE DE FRANCEInventors: Jean-Maurice Mallet, Solange Lavielle, Rodrigue Marquant, Alain Prochiantz, Ariel Di Nardo, Damien Testa
-
Patent number: 11359027Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.Type: GrantFiled: June 22, 2017Date of Patent: June 14, 2022Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Sébastien Maury, José Cohen, Benoît Salomon, Sina Naserian, Mathieu Leclerc
-
Publication number: 20220178949Abstract: The invention relates to a process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.Type: ApplicationFiled: May 2, 2019Publication date: June 9, 2022Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Le Duy DO, Jérôme HONNORAT, Véronique ROGEMOND
-
Patent number: 11352372Abstract: The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.Type: GrantFiled: June 5, 2019Date of Patent: June 7, 2022Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: John Liddle, Ann Louise Walker, Gemma Victoria White, Alexis Denis, Nerina Dodic, Marie-Hélène Fouchet, Anne Bouillot
-
Patent number: 11351156Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. The inventors questioned this concept, by mapping differential isoform-specific downstream signalling in response to their constant selective inhibition in pancreatic cancer, a disease currently without therapy. They identified common and specific signals activated by each PI3K isoform. These data make the rational for the development of highly selective PI3K isoform drugs used in combination, instead of compounds inhibiting all PI3Ks. In particular, the inventors showed that combined p110a and 110? inhibition is the most efficient strategy for pancreatic cancer patients.Type: GrantFiled: October 12, 2018Date of Patent: June 7, 2022Assignees: INSERM, Université Paul Sabatier Toulouse III, CNRS, Klinikum Rechts der Isar der Technischen Universität MünchenInventors: Julie Guillermet-Guibert, Maximillian Reichert, Célia Cintas
-
Patent number: 11352627Abstract: This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.Type: GrantFiled: October 24, 2018Date of Patent: June 7, 2022Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Sandrine Bourdoulous, Anaïs Domingot, Camille Faure
-
Patent number: 11351180Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.Type: GrantFiled: March 18, 2016Date of Patent: June 7, 2022Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, UNIVERSITE LAVALInventors: Manuel Rosa-Calatrava, Olivier Terrier, Julien Textoris, Guy Boivin, Mario Pizzorno
-
Patent number: 11351226Abstract: Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoïesis and a prolonged period of T-cell immunodeficiency. Understanding the mechanisms that govern thymic regeneration is of paramount interest for the recovery of a functional immune system notably after bone marrow transplantation (BMT). Here, the inventors show that administration of RANK ligand (RANKL) after total body irradiation and BMT boosts thymic regeneration. Notably, this treatment is also beneficial upon BMT in aged individuals. The inventors show that RANKL can improve thymopoiesis in aged individuals affected by thymic involution. Finally, the inventors show that RANK receptor is conserved in the human thymus. Accordingly, one aspect of the present invention relates to a method of boosting thymic regeneration in a patient suffering from a thymic injury comprising administering to the subject a therapeutically effective amount of a RANKL polypeptide.Type: GrantFiled: February 26, 2018Date of Patent: June 7, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Magali Irla, Noella Lopes
-
Patent number: 11344372Abstract: Systems, instruments, and methods are provided verifying that a robotic surgery is being performed in accordance with a surgical plan, wherein a surgical tool having a sensor outputs a data signal that enables the trajectory of the surgical tool to be displayed as an overlay on an image of an anatomical portion of a patient and a visual or audible signal that confirms the surgical tool is penetrating the anatomical portion in accordance with the surgical plan and/or that issues an alert indicating that the surgical tool is not being inserted into the anatomical portion according to the surgical plan.Type: GrantFiled: May 28, 2021Date of Patent: May 31, 2022Assignees: SpineGuard Vincennes, Sorbonne Universite, INSERM (Institute National de la Sante et de la Recherche, Centre National de la Recherche Scientifique—CNRSInventors: Maurice Bourlion, Olivier Frezal, Guillaume Morel, Stephane Bette, Thibault Chandanson, Florian Richer, Valentin Kerspern
-
Publication number: 20220160716Abstract: A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases.Type: ApplicationFiled: March 20, 2020Publication date: May 26, 2022Applicants: SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), MANROS THERAPEUTICSInventors: Thomas FALGUIERES, Virginie VAUTHIER, Laurent MEIJER, Nassima OUMATA
-
Patent number: 11339406Abstract: The present invention relates to variants of acid-alpha glucosidase and uses thereof.Type: GrantFiled: September 12, 2017Date of Patent: May 24, 2022Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNEInventors: Federico Mingozzi, Giuseppe Ronzitti
-
Patent number: 11335019Abstract: The present invention concerns a method for the 3D reconstruction of a scene comprising the matching (610) of a first event from among the first asynchronous successive events of a first sensor with a second event from among the second asynchronous successive events of a second sensor depending on a minimisation (609) of a cost function (E).Type: GrantFiled: March 15, 2016Date of Patent: May 17, 2022Assignees: SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Ieng Sio-Hoi, Benosman Ryad, Shi Bertram